May 6, 2014 - *Corresponding author: Rafael Rios, Monoclonal Gammopathies Unit, University .... Federico A, D'Aiuto E, Borriello F, Barra G, Gravina AG, et al. (2010) ... Ríos R, Jiménez-Moleón JJ, Sáinz J, López F, Rivera AB, et al (2011) ...
Leukemia
Tamayo et al., J Leuk 2014, 2:2 http://dx.doi.org/10.4172/2329-6917.1000e109
Editorial
Open Access
Obesity and Multiple Myeloma: What Do the Data Tell Us? Rafael Rios Tamayo1,2, Juan Sáinz Perez1,2, Jose Juan Jimenez-Moleon3,4 and Manuel Jurado Chacon1,2 Monoclonal Gammopathies Unit, University Hospital Virgen de las Nieves, Granada, Spain Genomic Oncology Area, Genyo (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), Granada, Spain 3 CIBER Epidemiology and Public Health, Granada, Spain 4 Department of Preventive Medicine and Public Health, University of Granada, Granada, Spain 1 2
Obesity is a major public health problem throughout the world. It is defined as an excess accumulation of adipose tissue, which is considered as a heterogeneous and highly active endocrine and metabolic organ [1]. Obesity predisposes individuals to an increased risk of developing many diseases, including atherosclerosis, nonalcoholic fatty liver disease, Type 2 Diabetes (T2D), asthma and cancer; it is also associated with altered functioning of circulating immune cells [2]. The Body Mass Index (BMI) is one of several indicators of body fat, which is calculated as weight in kilograms divided by height in meters squared and categorized as defined by the World Health Organization as “underweight” (BMI
